Capital Raising

Distressed companies can't raise on the standard CQ playbook. The dimensions still apply, but the weights shift, the narrative changes, and the investor pool is completely different. Here's how SCN works with founders in turnaround mode.

Second and third rounds aren't easier than the first. They're harder, and the CQ bar is higher. Here's what changes in the dynamics, why existing investors raise the bar, and how to score what your next round actually requires.

Most founders score in the CQ 40 to 60 range and stay there. The ones who climb to investor-ready do it in 60 days with a tactical playbook, not a strategy session. Here's the day-by-day sequence SCN runs with mid-range founders.

International founders face structural disadvantages when raising US capital. Legal entities, US presence requirements, investor familiarity, network access. Here's how Capital Quotient adapts for cross-border raises and what SCN has learned from working with founders across MENA, Africa, Europe, and Asia.

Hardware and deeptech founders raise into a system built for software. Capital Quotient adapts for capital-intensive, longer-cycle businesses. Here's what hardware investors actually grade you on and how to score it.

Healthcare and biotech founders face fundraising dynamics nothing else does: regulatory cliffs, clinical trial dependencies, longer sales cycles. Here's how Capital Quotient adapts for healthcare and what investors actually grade you on.